23 September 2019
Announcing the winner of the 2019 Bioanalysis Outstanding Contribution Award (BOSCA)
Bioanalysis Zone today announced the winner of the Bioanalysis Outstanding Contribution Award – BOSCA – awarded to bioanalytical scientists for outstanding work and contribution to the community.
Bioanalysis Zone and Bioanalysis, published by Future Science Group, are pleased to announce the winner of the 2019 Bioanalysis Outstanding Contribution Award (BOSCA).
After much deliberation, the judges agreed that Kevin Bateman of Merck (NJ, USA) was the most deserving of the title this year due to his outstanding research contributions, influence and engagement in the bioanalytical community.
“The competition for this award in 2019 included a large number of key players in the field of quantitative bioanalysis, all of whom were individually deserving of this award. It therefore speaks volumes about the recipient that Kevin was the winner. Kevin is a positive and enthusiastic leader in the field of quantitative bioanalysis. His forward thinking and vision of where we need to go as a community and how we get there are unparalleled. He is a leader in technological innovation and has a gift for turning ideas into reality, particularly where brave decisions need to be made about step changes in technology and workflows,” commented judge Neil Spooner (Spooner Bioanalytical Solutions; Hertford, UK) on behalf of the panel.
“Importantly and uniquely, what really makes Kevin stand out is his generosity with his knowledge, so enabling the pharmaceutical bioanalytical community to progress with technology in unison. I am honored to have Kevin as both a colleague and a friend and look forward to giving him this award at the upcoming Reid Bioanalytical Forum.”
Bioanalysis and Bioanalysis Zone would like to extend their congratulations to Dr Bateman and thank him for the exceptional contributions that have led to the advancement of the bioanalytical field and community.
To celebrate the announcement of the 2019 BOSCA award winner, the following Bioanalysis articles have been made available free of charge to members of Bioanalysis Zone:
Additional work from Dr Bateman published with Bioanalysis can be found here.
About the Bioanalysis Outstanding Contribution Award
Launched in 2014, the Bioanalysis Outstanding Contribution Award (BOSCA) aims to recognize exceptional scientists who have not only contributed in a technical manner, namely advancing bioanalytical processes and our fundamental knowledge in the field, but also helped shape the community through their participation in societies, groups and the organization of conferences.
About Bioanalysis Zone
Since launching in 2011, Bioanalysis Zone has attracted over 11,000 active members from the global bioanalytical community, representing the pharmaceutical, biotech and CRO industries, along with academia and healthcare. Each month, thousands of members visit the site to read industry news, original research exclusive interviews, webinars and commentaries. Join the Bioanalysis Zone Twitter and LinkedIn group for updates.
Bioanalysis is a MEDLINE-indexed journal covering the latest scientific, technical and regulatory developments relevant to those working on the analysis of xenobiotics and biotics in biological matrices. This is, primarily, bioanalysts working in pharmaceutical research and development, clinical laboratories, clinical toxicologists, forensic toxicologists and sports doping analysts.
About Future Science Group
Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological and scientific research. FSG’s portfolio consists of three publishing imprints, Future Science, Future Medicine, Newlands Press, as well as a content development imprint, PharmaPlatforms. In addition to a core business of subscription and open access journal publishing, FSG develops specialist knowledge networks and content hubs, enabling professionals to easily connect and collaborate with their peers in niche scientific fields.
The aim of Future Science Group is to serve the advancement of clinical practice and drug research by enhancing the efficiency of communication among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards. www.future-science-group.com